BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 04/06/21

Brooklyn Immuno Therapeutics (BTX) +77%.Scienjoy Holding (SJ) +37% on strategic alliance with Snipp.Weidai (WEI) +26%.Elite Education Group International (EEIQ) +16%.Phunware (PHUN) +12%. as board authorizes bitcoin purchases for Blockchain Ecosystem Launch.Romeo Power (RMO) +12% as...

Brooklyn ImmunoTherapeutics , Inc. (NYSE American: BTX) ("Brooklyn" or “the Company”), a biopharmaceutical company focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, today announced the appointment of Howard J. Federoff...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning and ger ready for the stock market today! If you want to be ready for the market when it opens today, you’ll want to make sure you know the biggest pre-market stock movers this morning. Source: Shutt...

Shares of Brooklyn ImmunoTherapeutics to commence trading on the NYSE American on March 26, 2021 under the new ticker symbol “BTX” Immediately prior to the closing of the merger, there was a one for two reverse stock split of the outstanding shares of common st...

BioTime, Inc (BTX) Q2 2019 Earnings Conference Call August 8, 2019 16:30 ET Company Participants Ioana Hone - Director, Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Ed Wirth - Chief Medical Officer Gary Hogge - Senior Vice...

BioTime (NYSEMKT: BTX ): Q2 GAAP EPS of -$0.20 misses by $0.14 . Revenue of $0.78M (-69.3% Y/Y) beats by $0.22M . Shares -1% . Press Release More news on: BioTime, Inc., Earnings news and commentary, Healthcare stocks news, ,

Announced Rebranding and Name Change to Lineage Cell Therapeutics and Corporate Relocation Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen ® Conducted Sale of 2.25 Million Shares of OncoCyte Corporation Initiated...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it will report its second quarter 2019 financial and operating results on Thursday, August 8 th , 2019, following the close of th...

New Identity Reflects Commitment to Becoming a Leading Cell Therapy Company Company to Trade on NYSE American Under Ticker “LCTX” at Market Open on August 12, 2019 BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel ce...

The first patient has been dosed with BioTime's ( BTX ) new off-the-shelf Thaw-and-Inject formulation of OpRegen using the Orbit Subretinal Delivery System (Orbit SDS) in a Phase 1/2a clinical trial in patients with dry age-related macular degeneration. More news on: BioTime, Inc., Hea...